Table 1.

Successful RNAi strategies targeting HBV utilising genomic conservation.

Group	Design of the RNAi effector	RNAi approach	Experimental system	Nucleotide position*	Designated name	Target sequence	RNAi effect (% reduction)	Ref.
				416–434	Sh6	CTGCTATGCCTCATCTTCT	95% (encapsidated pgRNA), 98% (DNA)
				458–476	1740 SLAS	GGTATGTTGCCCGTTTGTC	92% (encapsidated pgRNA), 96% (DNA)
				720–738	Sh10	CTGTTTGGCTTTCAGTTAT	95% (encapsidated pgRNA), 98% (DNA)	[7]
				1823–1841	DR1	TTTCACCTCTGCCTAATCA	96% (DNA)
				1848–1867	Eps32	TTCATGTCCCTACTGTTCAA	96% (DNA)
I	Sequence conservation among HBV genotypes	shRNA expression vector (Pol II/III promoter)	Liposome delivery/human liver cell line	2421–2439	Sh1	GTCGCAGAAGATCTCAATC	86% (encapsidated pgRNA), 96% (DNA)
				458–476	S1	GGTATGTTGCCCGTTTGTC	90% (total RNA, DNA)	[10]
				1317–1337	PRE1317	AAAGCTCATCGGAACTGACAA	80% (cccDNA)	[14]
				245–265	B245	AGTCTAGACTCGTGGTGGACT	~80% (pgRNA, pcRNA), 90% (DNA)
				376–396	B376	GATGTGTCTGCGGCGTTTTAT	~80% (pgRNA, pcRNA, DNA)	[13]
				1581–1601	B1581	GCACTTCGCTTCACCTCTGCA	~70% (pgRNA, pcRNA), 80% (DNA)
				1778–1798 (sic)	B1789	AGGCTGTAGGCATAAATTGGT	~70% (pgRNA, pcRNA) 80% (DNA)
II	Sequence conservation among HBV genotypes	miRNA expression vector (Pol II promoter)	Liposome delivery/human liver cell line	761–782	Mir-155-S608	CCAAGTCTGTACAGCATCGTGA	80% (HBs mRNA)	[52]
				1575–1599	Mir-51/5 Mir-122/5	CCGTGTGCACTTCGCTTCACCTCTG	90% (HBsAg)	[24]
III	Analysis of a single genotype (representative examples)	shRNA expression vectors (Pol III promoter)	Viral vectors/human liver cell line	456–476	S1	AAGGTATGTTGCCCGTTTGTC	90% (Total RNAs)	[40]
				1644–1664	X1	AAGGTCTTACATAAGAGGACT	90% (Total RNAs)
				322–342	S1	AACCTCCAATCACTCACCAAC	80% (HBsAg)
				540–560	S2	AAGGAACCTCTATGTATCCCT	80% (HBsAg)	[53]
				589–609	S3	AAATTGCACCTGTATTCCCAT	80% (HBsAg)

*indicates EcoRI site-based numbering systems using Genotype A (AM282986) as described in [6].